Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination
- 1 July 2015
- journal article
- Published by Elsevier in Clinical Therapeutics
- Vol. 37 (7) , 1433-1442
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Science and Technology (2009-0094050)
- National Research Foundation of Korea
This publication has 25 references indexed in Scilit:
- HBV Dna Level at 24 Weeks is the Best Predictor of Virological Response to Adefovir Add-On Therapy in Patients with Lamivudine ResistanceAntiviral Therapy, 2012
- Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological responseHepatology, 2011
- Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistanceHepatology International, 2011
- Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis BGut, 2010
- Efficacy of adefovir add‐on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine‐resistant chronic hepatitis BJournal of Medical Virology, 2010
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- Low Resistance to Adefovir Combined With Lamivudine: A 3-Year Study of 145 Lamivudine-Resistant Hepatitis B PatientsGastroenterology, 2007
- Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis BHepatology, 2007
- Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine†Hepatology, 2005
- Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapyHepatology, 2001